---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-047599"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2026-04-24T23:59:59+00:00"
generated_at: "2026-05-15T04:11:47.886445+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma raises $5M via registered direct offering and private placement

## Summary
- Sold 5,076,143 shares/pre-funded warrants at $0.985 each; raised ~$5M gross, $4.5M net.
- Issued unregistered warrants to purchase 5,076,143 shares at $0.86, 5-year term, cashless exercise.
- Net proceeds to fund commercial launch of LYMPHIR and development of product candidates.
- 45-day lock-up on further equity issuance after closing; H.C. Wainwright acted as placement agent.

## SEC filing metadata
- accession: 0001213900-26-047599
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2026-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390026047599/0001213900-26-047599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390026047599/ea0287620-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-047599
- JSON: https://secwatch.observer/filing/0001213900-26-047599.json
- Plain text: https://secwatch.observer/filing/0001213900-26-047599.txt

## Source-grounded claims
- claim_id: 3ceadf1e7f1f93c3d8a70d32343d620962e0818c
  claim: Citius Pharmaceuticals, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $5.0 million (effective 2026-04-23).
  evidence_excerpt: On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warrants”) at an offering price of $0.985 and $0.9849, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390026047599/0001213900-26-047599-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.